Repatha SureClick is a prefilled autoinjector used to lower LDL cholesterol (often called “bad” cholesterol) in people whose levels remain too high despite diet and other medications. It is FDA-approved for three main purposes: treating primary hyperlipidemia in adults, reducing the risk of heart attacks and strokes in people with established cardiovascular disease, and lowering LDL cholesterol in patients with inherited high cholesterol conditions known as familial hypercholesterolemia.
How Repatha Works
Your liver removes LDL cholesterol from the bloodstream using specialized receptors on its surface. A protein called PCSK9 normally breaks down these receptors, which means fewer are available to clear cholesterol. Repatha is a monoclonal antibody that blocks PCSK9, allowing more receptors to survive and pull LDL out of the blood. The result is a significant drop in circulating LDL cholesterol, typically 50% to 60% from baseline in clinical trials.
Approved Uses
Primary Hyperlipidemia and Cardiovascular Risk
For adults with high cholesterol that hasn’t responded well enough to statins or other lipid-lowering drugs, Repatha can be added to bring LDL levels down further. It’s also specifically approved to reduce the risk of heart attack, stroke, and coronary procedures in adults who already have atherosclerotic cardiovascular disease, meaning plaque has built up in their arteries.
Long-term data from the FOURIER trial, published in Circulation, showed that patients on Repatha had a 20% lower risk of cardiovascular death, heart attack, or stroke compared to those on placebo. The risk of cardiovascular death specifically was 23% lower.
Familial Hypercholesterolemia
Some people inherit genes that cause dangerously high cholesterol from birth. Repatha is approved for two forms of this condition. Heterozygous familial hypercholesterolemia (HeFH), where one copy of the gene is affected, can be treated in adults and children aged 10 and older. Homozygous familial hypercholesterolemia (HoFH), the more severe form where both gene copies are affected, is also treatable in adults and children aged 10 and older.
In real-world use among patients with HeFH, LDL cholesterol dropped by about 59% over two years, bringing average levels down to around 80 mg/dL. For HoFH patients, the reduction was roughly 58% at the last follow-up, though results depend on how much residual receptor activity a person’s liver retains. Patients with very little receptor function may see smaller reductions.
The SureClick Device and Dosing
The SureClick autoinjector delivers a single 140 mg dose of Repatha in 1 mL of solution. You inject it under the skin of your thigh, abdomen, or upper arm. The device is designed for home use: you press it against your skin, click to start the injection, and hold it in place until the window on the device indicates the dose is complete.
For most conditions, there are two dosing schedules to choose from: one injection of 140 mg every two weeks, or three injections of 140 mg (totaling 420 mg) once a month. Your prescriber will decide which schedule fits your situation. For HoFH that doesn’t respond adequately after 12 weeks, the monthly dose can be increased to 420 mg every two weeks.
Storage Requirements
Repatha SureClick should be stored in the refrigerator between 36°F and 46°F (2°C to 8°C), kept in its original carton to protect it from light. If needed, you can store it at room temperature (up to 77°F or 25°C) for up to 30 days. After 30 days at room temperature, the medication must be discarded. Do not freeze it or expose it to heat.
Common Side Effects
Most side effects reported with Repatha are mild and occur at rates only slightly higher than with placebo. In a year-long clinical trial of adults with high cholesterol, the most frequently reported issues were cold-like symptoms such as nasopharyngitis (10.5% vs. 9.6% on placebo), upper respiratory infections (9.3% vs. 6.3%), and flu (7.5% vs. 6.3%). Back pain, muscle pain, headache, and dizziness each occurred in 3% to 6% of patients.
Injection site reactions, including redness, pain, and bruising, affected about 3% to 6% of patients, which was nearly identical to placebo rates. In the large cardiovascular outcomes trial, the side effect profile was similar. New diabetes diagnoses were slightly more common among Repatha users (8.8%) than placebo users (8.2%), though this small difference makes it difficult to draw firm conclusions.
In children treated for familial hypercholesterolemia, headache was notably more common with Repatha (11%) compared to placebo (2%), along with sore throat (7% vs. 0%). These findings come from shorter-duration pediatric studies, so the long-term picture in younger patients is still developing.
Who Repatha May Not Be Right For
Repatha is always used alongside diet changes and typically on top of statins or other cholesterol medications, not as a replacement for them. It is not a first-line treatment for ordinary high cholesterol. It’s generally prescribed when statins alone aren’t enough, when a person can’t tolerate statins, or when inherited cholesterol conditions require more aggressive lowering. The medication is a biologic, meaning it’s a lab-made antibody, so anyone with a known serious allergic reaction to evolocumab or any of its ingredients should not use it.